NCT01848249

Brief Summary

Compared to chronic dialysis, kidney transplantation provides recipients with longer survival and better quality of life at a lower cost. In order to meet increasing demands for kidney allografts, kidneys from older and sicker donors are being procured. This has led to greater discard rates of donated kidneys as well as more complications for recipients, including shorter allograft survival. Available clinical models to predict kidney allograft quality have poor prognostic ability and do not asses the degree of kidney allograft injury. However, allograft injury near the time of procurement can lead to major consequences for the transplant recipient: greater risks of delayed graft function, poor allograft function and premature loss of the transplant. Our proposal is based on the hypotheses that novel biomarkers measured in donor urine and transport media at the time of procurement can assess acute and chronic kidney injury and that distinct biomarker patterns will predict allograft survival. In collaboration with five organ procurement organizations, we will collect urine samples from consecutive deceased donors and samples of transport solution for every pumped kidney. We will measure markers of injury, repair, inflammation and fibrosis. We will determine mortality and allograft survival in all patients by linkage to the United Network for Organ Sharing (UNOS) database (Overall Cohort). Additionally, we will perform a detailed chart review of a subset of recipients (detailed cohort) and will also examine associations between biomarkers and longitudinal graft function over five years after transplant. Early, non-invasive and rapid assessment of donor kidney injury could drive better allocation decisions and potentially reduce the rates of post-transplant complications. Further, these new tools could provide a platform for clinical trials of therapies for allografts and kidney transplant recipients aimed at ameliorating allograft injury.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,679

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2010

Longer than P75 for all trials

Geographic Reach
1 country

17 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2010

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

April 30, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 7, 2013

Completed
6.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
Last Updated

April 9, 2020

Status Verified

April 1, 2020

Enrollment Period

9.6 years

First QC Date

April 30, 2013

Last Update Submit

April 8, 2020

Conditions

Keywords

deceased donorskidney donortransplant recipientskidney transplantdelayed graft functionbiomarkersend stage renal diseasegraft failure

Outcome Measures

Primary Outcomes (2)

  • Delayed Graft Function

    Receipt of dialysis within the first seven days post renal transplant

    Assessed within first week of receiving renal transplant

  • Death-Censored Graft Failure (Overall Cohort)

    Requirement of chronic dialysis or retransplantation after renal transplant.

    median of 4 years of follow-up

Secondary Outcomes (1)

  • Graft Function (detailed cohort)

    median of 4 years of follow-up

Study Arms (2)

Deceased-Donor Cohort

We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).

Recipient Cohort (Overall and Detailed)

No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The population from which our Deceased-Donor Cohort will be selected is all potential deceased organ donors located in the regions serviced by our participating organ procurement organizations (OPOs). The recipient cohorts will be defined by the deceased donors enrolled in the study, and thus, the study population for this group is all recipients of kidneys from deceased organ donors procured in the regions serviced by our participating OPOs.

You may qualify if:

  • Donor Cohort: Appropriate informed consent for research according to OPO policies
  • Recipient Cohorts: Any recipient of at least one kidney from a deceased donor enrolled by our participating OPOs

You may not qualify if:

  • Donor Cohort: Lack of adequate biospecimen quantity or quality as per protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

Yale New Haven Hospital

New Haven, Connecticut, 06510, United States

Location

University of Maryland Medical Center

Baltimore, Maryland, 21201, United States

Location

New England Organ Bank

Waltham, Massachusetts, 02451, United States

Location

Gift of Life Michigan

Ann Arbor, Michigan, 48108, United States

Location

Harper University Hospital

Detroit, Michigan, 48201, United States

Location

St. Barnabas Medical Center

Livingston, New Jersey, 07039, United States

Location

New Jersey Sharing Network

New Providence, New Jersey, 07974, United States

Location

Newark Beth Israel Medical Center

Newark, New Jersey, 07112, United States

Location

New York Organ Donor Network

New York, New York, 10001, United States

Location

Mount Sinai School of Medicine

New York, New York, 10029, United States

Location

NewYork-Presbyterian/ Columbia University Irving Medical Center

New York, New York, 10032, United States

Location

The New York Hospital (Cornell)

New York, New York, 10065, United States

Location

Montefiore Medical Center

New York, New York, 10467, United States

Location

Hahnemann University Hospital

Philadelphia, Pennsylvania, 19102, United States

Location

Gift of Life Donor Program- Philadelphia

Philadelphia, Pennsylvania, 19104, United States

Location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

Location

Related Publications (5)

  • Hall IE, Bhangoo RS, Reese PP, Doshi MD, Weng FL, Hong K, Lin H, Han G, Hasz RD, Goldstein MJ, Schroppel B, Parikh CR. Glutathione S-transferase iso-enzymes in perfusate from pumped kidneys are associated with delayed graft function. Am J Transplant. 2014 Apr;14(4):886-96. doi: 10.1111/ajt.12635. Epub 2014 Feb 24.

  • Hall IE, Reese PP, Weng FL, Schroppel B, Doshi MD, Hasz RD, Reitsma W, Goldstein MJ, Hong K, Parikh CR. Preimplant histologic acute tubular necrosis and allograft outcomes. Clin J Am Soc Nephrol. 2014 Mar;9(3):573-82. doi: 10.2215/CJN.08270813. Epub 2014 Feb 20.

  • Liu C, Hall IE, Mansour S, Thiessen Philbrook HR, Jia Y, Parikh CR. Association of Deceased Donor Acute Kidney Injury With Recipient Graft Survival. JAMA Netw Open. 2020 Jan 3;3(1):e1918634. doi: 10.1001/jamanetworkopen.2019.18634.

  • Puthumana J, Hall IE, Reese PP, Schroppel B, Weng FL, Thiessen-Philbrook H, Doshi MD, Rao V, Lee CG, Elias JA, Cantley LG, Parikh CR. YKL-40 Associates with Renal Recovery in Deceased Donor Kidney Transplantation. J Am Soc Nephrol. 2017 Feb;28(2):661-670. doi: 10.1681/ASN.2016010091. Epub 2016 Jul 22.

  • Yaffe HC, von Ahrens D, Urioste A, Mas VR, Akalin E. Impact of Deceased-donor Acute Kidney Injury on Kidney Transplantation. Transplantation. 2024 Jun 1;108(6):1283-1295. doi: 10.1097/TP.0000000000004848. Epub 2023 Nov 22.

Related Links

Biospecimen

Retention: SAMPLES WITHOUT DNA

((A)) Urine Samples: At time of deceased donor nephrectomy ((B)) Perfusates: At time of initiation and stopping of machine perfusion

MeSH Terms

Conditions

Acute Kidney InjuryDelayed Graft FunctionKidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsRenal Insufficiency, ChronicChronic DiseaseDisease Attributes

Study Officials

  • Chirag R Parikh, MD PhD

    Yale University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 30, 2013

First Posted

May 7, 2013

Study Start

May 1, 2010

Primary Completion

December 1, 2019

Study Completion

March 1, 2020

Last Updated

April 9, 2020

Record last verified: 2020-04

Locations